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Non-invasive imaging of the coronary arteries
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Non-invasive imaging of the coronary arteries is an enterprise in rapid development. From the research perspective, there is great demand
for in vivo techniques that can reliably identify features of high-risk plaque that may offer insight into pathophysiological processes and act
as surrogate indicators of response to therapeutic intervention. Meanwhile, there is clear clinical need for greater accuracy in diagnosis
and prognostic stratification. Fortunately, ongoing technological improvements and emerging data from randomized clinical trials are
helping make these elusive goals a reality. This review provides an update on the current status of non-invasive coronary imaging with
computed tomography, magnetic resonance, and positron emission tomography with a focus on current clinical applications and future re-
search directions.
...................................................................................................................................................................................................
Keywords Coronary heart disease • Computed tomography • Positron emission tomography • Magnetic resonance
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Introduction
Despite remarkable diagnostic and therapeutic advances in recent
decades, coronary heart disease remains the largest single cause of
death in Europe.1 In order to address this residual burden of morbid-
ity and mortality, clinicians need greater access to imaging techniques
that can improve the detection and prognostic classification of
patients at risk of cardiovascular events.
Non-invasive imaging of the coronary arteries holds genuine
promise that these hopes may be realized via both well-established
diagnostic technologies, such as computed tomography coronary
angiography (CTCA), and exciting new developments such as posi-
tron emission tomography (PET) and magnetic resonance coronary
angiography (MRCA). Indeed, the results of large multicentre clinical
trials are now emerging which will help clarify the optimal strategies
for incorporating such tools into clinical practice.
To better understand the role and relative merits of the various
options for non-invasive imaging, it is helpful to appreciate the proc-
esses of plaque biology and pathophysiology. Such background know-
ledge holds relevance to clinicians as it informs the rationale for
imaging coronary atherosclerosis and the histological processes that
we endeavour to identify through these investigations.
Plaque biology as it relates to
non-invasive imaging
Atherosclerosis is a chronic inflammatory disease characterized by
the formation of lipid-rich plaques. Intimal thickening is a near univer-
sal development by early adulthood and begins with an increase in
vascular smooth muscle cells within the subintimal space. This is asso-
ciated with concurrent insudation of circulating lipoproteins across
the vascular endothelium where they are bound by an extracellular
proteoglycan rich matrix. Oxidation of these lipoproteins initiates an
inflammatory cascade as endothelial and smooth muscle cells express
cellular adhesion molecules that promote migration and differenti-
ation of circulating monocytes. The resultant macrophages, particu-
larly the M1-subtype, act to promote a persistent maladaptive
response leading to the development of the archetypal high-risk pla-
que; the thin-cap fibroatheroma. The hallmarks associated with high-
risk plaque can be loosely categorized as those either related to the
macroscopic structure of the plaque or to the biological processes
occurring within it. Indeed, histological and imaging data have consist-
ently demonstrated that culprit plaques responsible for myocardial
infarction have the following characteristics: a large plaque volume,
a lipid-rich necrotic core, positive remodelling, peripheral
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neovascularization, micro-calcification, intra-plaque haemorrhage,
chronic inflammation, and a thin fibrous cap. Each of these character-
istics represents a potential imaging target for in vivo identification of
high-risk plaques and for guiding subsequent therapeutic modification
(Figure 1).2
Aims of non-invasive coronary
imaging
In evaluating the clinical role of non-invasive imaging, it is important
to distinguish between patients based on the presence or absence of
symptoms likely to be related to myocardial ischaemia. The former
group comprises individuals with suspected stable angina pectoris or
possible acute coronary syndromes. Here, the diagnostic objective is
to identify or to exclude the presence of obstructive plaque causing
sufficient luminal compromise that myocardial blood flow may be in-
sufficient to meet metabolic demand. In contrast, coronary imaging in
the asymptomatic population is largely targeted at estimating the risk
of future events through the identification of atherosclerotic burden
including non-obstructive disease and high-risk plaque (Figure 2). This
review focusses on non-invasive imaging of coronary plaque struc-
ture and pathophysiology and will not describe the additional utility
of these modalities in the assessment of coronary flow and myocar-
dial ischaemia.
The four most developed non-invasive coronary imaging modal-
ities include computed tomography coronary artery calcium (CAC)
scoring, CTCA, MRCA, and positron PET—usually employed in
combination with either computed tomography or magnetic reson-
ance imaging (Table 1).
Coronary artery calcium scoring
Atherosclerotic calcification is a well-described process, in part
occurring as a healing response to pathological inflammation within
the plaque. In its earliest stages, extracellular debris acts as a nidus for
calcium deposition and the resultant microcalcifications have been
shown to increase the likelihood of rupture of the surface of fibro-
atheromas. In more advanced disease—by which stage calcium is de-
tectable on computed tomography—these microcalcifications
coalesce into large, calcific nodules.
The assessment of coronary artery calcification, is one of the most
enduring applications for non-invasive coronary artery imaging. The
relationship between coronary calcification and obstructive coronary
artery disease was initially determined from chest radiography and
confirmed with findings from in vivo invasive coronary angiography
and ex vivo histology.3,4 The subsequent introduction of electron-
beam computed tomography substantially improved diagnostic sensi-
tivity, and scans are now commonly performed on non-contrast
images obtained from multi-detector computed tomography scan-
ners at sub-millisevert radiation doses.5 The CAC scan consists of a
non-contrast, gated computed tomography of the heart acquired
during a short period of held inspiration. Arterial calcium is defined as
the presence of a lesion with a density >130 Hounsfield units across
an area of at least 1 mm2. Atherosclerotic calcification can be
reported by volume or mass, but most commonly is described in
Figure 1 Imaging targets of high-risk plaque. Reused from Adamson et al.2 Circulating monocytes migrate into early intimal thickening where they
phagocytose lipid becoming foam cells and activated macrophages detectable on 68Ga-DOTATATE positron emission tomography. Vascular remod-
elling can be detected on computed tomography coronary angiography prior to luminal stenosis developing. As the lipid core develops this can be
detected as low-density signal on computed tomography coronary angiography. The resulting hypoxic environment prompts neovascularization
with friable vessels prone to intraplaque haemorrhage, both of which can be detected on magnetic resonance coronary angiography. A necrotic core
develops with microvesicles arising from apoptotic macrophages and vascular smooth muscle cells giving rise to microcalcifications detectable on
18F-fluoride positron emission tomography before coalescing into more stable calcific nodules detectable on computed tomography calcium scans.
Rupture of the fibrous cap may result in intraluminal thrombosis detectable on magnetic resonance coronary angiography.
2 P.D. Adamson and D.E. Newby
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy670/5156200 by Edinburgh U
niversity user on 16 N
ovem
ber 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.Agatston units (AU), a semi-quantitative measure that incorporates
aspects of calcium density and distribution. Coronary calcium scoring
has been evaluated both in patients with suspected angina and asymp-
tomatic populations.
Uncertainty persists regarding the utility of CAC scoring
amongst symptomatic individuals. In these patients, a CAC
score of >0 has a diagnostic sensitivity for identifying a coron-
ary stenosis of >_50% of between 0.89 and 0.99.6–8 However,
the corresponding specificity is poor, ranging from 0.40 to 0.59.
Consequently, in low-risk populations, such as patients with
atypical symptoms in the outpatient clinic, the low positive pre-
dictive value will necessitate additional diagnostic imaging in
many cases. Conversely, in situations with high pre-test prob-
ability of disease, for example, amongst troponin positive
patients in the Emergency Department, the test will have an
unacceptably high ‘false-negative’ rate. This is a particular con-
cern as non-calcified plaques often exhibit additional high-risk
features on alternative imaging modalities and are therefore
more likely to rupture with resultant myocardial infarction.
Consequently, CAC scoring is not recommended in the diag-
nostic assessment of symptomatic chest pain patients.
Accepting that not all plaques contain calcium detectable on com-
puted tomography, the total CAC score has been demonstrated in
histopathological and intravascular ultrasound studies to offer an ac-
ceptable approximation of the overall plaque burden for an
individual. Given the association between CAC and both plaque bur-
den and coronary obstruction, it is perhaps unsurprising that numer-
ous reports have confirmed the prognostic value of such scores. The
risk stratification provided is in addition to established clinical and bio-
chemical risk factors, and the St Francis Heart Study found an im-
provement in the c-statistic for clinical events from 0.69 to 0.79 when
added to the Framingham risk score9; a finding that has been
confirmed in several larger cohort studies including the MESA (Multi-
Ethnic Study of Atherosclerosis),10 and HNR (Heinz Nixdorf
Recall—Risk Factors, Evaluation of Coronary Calcium and
Lifestyle)11 trials. This improvement is of most value in intermediate
risk patients without established cardiovascular disease who may be
considering whether to commence primary prevention therapies. In
this context, both the 2013 ACC/AHA and 2016 ESC guidelines on
the prevention of cardiovascular disease give a Class IIb (may be con-
sidered) recommendation to CACS.12,13
Computed tomography coronary
angiography
The clinical application of CTCA was long delayed by the problems
of cardiac motion and high radiation exposure. Fortunately, advances
in scanner technology and the introduction of prospective electro-
cardiographic (ECG)-gating have largely overcome these challenges
Figure 2 Complementary roles of non-invasive coronary imaging. The use of non-invasive coronary imaging can be considered in three contexts,
each with specific objectives that may inform the choice of imaging modality. (A) Computed tomography angiography provides accurate assessment
of coronary stenosis that can guide management of patients with suspected stable angina and rule out Type 1 myocardial infarction in patients with
potential acute coronary syndrome. (B) Coronary artery calcium scanning is able to reliably quantify overall atherosclerotic burden and improve risk
stratification in asymptomatic individuals. (C) T1-weighted magnetic resonance coronary angiography can identify features of atherosclerotic instabil-
ity including intracoronary thrombus and intraplaque haemorrhage and may be of value in suspected acute coronary syndrome or asymptomatic risk
stratification. (D) Positron emission tomography can employ specific tracers designed to target markers of plaque vulnerability that may improve
prognostic assessment or act as a surrogate of therapeutic response in asymptomatic patients.
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and diagnostic image quality can now be obtained in 95% of scans in
unselected populations.14 Where image quality remains poor, it is
commonly related to motion artefacts at high heart rates, dense cor-
onary calcification, or coronary stents. Such limitations can be
minimized through appropriate patient selection and preparation,
including judicious use of beta-blockers as part of the scanning proto-
col. Clinical imaging is performed on >_64-slice computed
tomography scanners, using intravenously administered contrast
media and can be performed with radiation exposures in the range of
3–5 mSv.
Computed tomography coronary
angiography as a diagnostic tool for
coronary obstruction
One of the earliest proposed uses for CTCA related to improving
the selection of patients presenting with suspected stable angina who
required invasive coronary angiography and initial studies on this
imaging modality focused on diagnostic accuracy with regards to
detecting or excluding obstructive CAD. A meta-analysis published
in 2007 described a sensitivity of 93% and specificity of 96% on a per-
segment basis for the detection of coronary stenoses >50%,15 and in
symptomatic patients with an intermediate pre-test probability of ob-
structive coronary artery disease, the negative predictive value of a
negative CTCA is reported to be >95%.16 Based on the results of
these diagnostic accuracy studies, CTCA has gained endorsement by
international guidelines as a reasonable choice of non-invasive test in
appropriately selected patients.17,18
Computed tomography coronary
angiography for prognosis
In addition to diagnosing coronary obstruction, the ability of CTCA
to accurately quantify the anatomical distribution and severity of cor-
onary atherosclerosis enables it to provide valuable prognostic infor-
mation. As for invasive imaging, there is a clear stepwise worsening of
....................................................................................................................................................................................................................
Table 1 Comparison of non-invasive coronary imaging modalities
Imaging parameters CT calcium scan CT coronary angiography MRCA PET
Image acquisition
Scan duration 0.5–10 s 0.5–10 s 10–20 min 60–90 min (tracer up-
take)15–30 min/PET
bed
Spatial resolution 1.5–3.0 mm 0.5–1.0 mm 1.0–2.0 mm 4.0–10.0 mm (tracer
dependent)
Temporal resolution 240–420 ms 240–420 ms (65 ms with dual-
source CT)
<60 ms Minutes
Radiation exposure <1 mSv 1–10 mSv (protocol dependent) Nil 6–15 mSv (less in PET-
MR)
Advantages Wide availability
Low cost
Low radiation exposure
Large evidence base to support
prognostic implications
Short scan time
Wide availability
Best spatial resolution
Robust evidence to support use
Radiation free imaging
Allows concurrent assess-
ment of cardiac function
Not limited by coronary
calcification
Soft tissue characterization
Tracers can be devel-
oped to target almost
any structural or
pathophysiological
process of interest
Limitations Limited spatial resolution
Non-calcified (potentially
high-risk) plaque not
detectable
Requires adequate heart rate
control
Risk of contrast reaction/
nephropathy
Imaging limited by dense coron-
ary calcification and stents
Radiation exposure
Limited spatial resolution
Prolonged scan duration
High cost
Limited availability
Claustrophobia
Metallic implants
Poor spatial resolution
Prolonged tracer uptake
time and long scan
duration
Relatively high radiation
exposure (PET-CT) al-
though this can be sub-
stantially reduced with
PET-MR
High cost
Very limited availability
Indications Risk stratification in primary pre-
vention for individuals at low-
intermediate risk of cardiovas-
cular events
Non-invasive assessment of
suspected stable angina in
patients with intermediate
pre-test probability of
coronary artery disease
Anomalous coronary arteries
Follow-up of Kawasaki dis-
ease (coronary aneurysms)
Assessment of coronary by-
pass grafts
Research purposes only
at present
CT, computed tomography; MRCA, magnetic resonance coronary angiography; PET, positron-emission tomography.
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prognosis associated with increasing numbers of diseased vessels.19
Indeed, due to its sensitivity in the detection of non-obstructive cor-
onary atheroma and ability to identify additional adverse plaque char-
acteristics, risk stratification is a particular strength of CTCA. As
previously mentioned, histopathological and invasive coronary imag-
ing studies have identified a number of features that are commonly
present in plaques at risk of coronary rupture.20 Correlates of these
features have been described for non-invasive imaging with CTCA
and include the presence of positive remodelling, low attenuation
plaque, spotty calcification, and the ‘napkin ring’ sign (Figure 3).21
More recently, changes in the composition of perivascular adipose
tissue have also been described that are detectable on CTCA, correl-
ate with histological evidence of plaque inflammation, and may arise
in response to paracrine signalling.22 Numerous studies have
reported an association between such adverse plaque characteristics
and an increased risk of subsequent cardiovascular events.19,21,23,24
Furthermore, as for quantification of coronary calcification, a variety
of prognostic scores have been described. At the simplest level, the
segment involvement score (SIS) sums the number of diseased cor-
onary segments, whilst the stenosis severity score (SSS) also incorpo-
rates a weighting factor for stenotic severity.19 More recently, the
computed tomography-adapted Leaman score, combining stenotic
severity, myocardium at risk, and high-risk plaque features, appears
to improve risk stratification further.25
Randomized controlled trials testing
computed tomography coronary
angiography
In contrast with most radiological investigations used in medical prac-
tice, the clinical utility of CTCA has been rigorously determined in a
series of randomized clinical trials. In a comparison with exercise
ECG testing, the CAPP (Cardiac CT for the Assessment of Pain and
Plaque) trial (n= 500) demonstrated an improvement in angina-
related quality of life, with the use of CTCA.26 This trial was under-
powered for hard clinical events but identified a corresponding
reduction in unplanned hospital admissions amongst those in the
CTCA intervention arm. More recently, the much larger PROMISE
(Prospective Multicenter Imaging Study for Evaluation of Chest Pain)
and SCOT-HEART (Scottish Computed Tomography of the
HEART) trials have reported their findings. PROMISE (n= 10 003)
randomized intermediate-risk symptomatic patients being evaluated
Figure 3 Adverse coronary plaque characteristics identified on computed tomography coronary angiography. Coronary atherosclerotic plaque
features detected using computed tomography coronary angiography including (A) positive remodelling—defined as an outer vessel diameter (large
yellow line) 10% greater than the mean diameter of the segments immediately proximal (small yellow line) and distal to the plaque; (B) low attenu-
ation plaque—defined as a focal central area of plaque with an attenuation density of <30 Hounsfield Units (yellow arrow); (C) spotty calcification—
defined as focal calcification within the coronary artery wall <3 mm in maximum diameter (yellow arrow); and (D) the ‘napkin ring’ sign—defined as a
central area of low attenuation plaque with a peripheral rim of high attenuation (yellow arrow).
Non-invasive imaging of the coronary arteries 5
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..for the presence of coronary heart disease to CTCA or non-invasive
functional testing (67% nuclear stress imaging, 23% stress echocardi-
ography, 10% exercise ECG).27 The median duration of follow-up
was 25 months and no difference in the primary composite endpoint
(death, myocardial infarction, hospitalization for unstable angina, or
major procedural complication) was demonstrated despite a down-
stream reduction in the rate of unnecessary invasive coronary angio-
grams and apparent reductions in death or myocardial infarction at
12 months. The SCOT-HEART trial (n= 4146) investigated the utility
of adding CTCA to standard care (predominantly exercise ECG) in a
broad population of patients seen in rapid access chest pain clinics
across Scotland.14 The primary endpoint of diagnostic certainty at 6-
weeks was increased with CTCA. Recently, the 5-year composite
clinical outcome of coronary death or non-fatal myocardial infarction
has been reported, with a marked 40% relative risk reduction in the
CTCA arm of the trial.28 In aggregate, these trials provide powerful
evidence of benefit for a CT first approach in the assessment of stable
chest pain.29
Randomized trials of CTCA have also been conducted in the
Emergency Department setting amongst patients with suspected
acute coronary syndromes. Examples include the CT-STAT
(Coronary Computed Tomographic Angiography for Systematic
Triage of Acute Chest Pain Patients to Treatment, n= 1370),
ROMICAT-II (Rule Out Myocardial Infarction/ischaemia Using
Computer Assisted Tomography, n= 1000), and ACRIN-PA (CT
Angiography for Safe Discharge of Patients with Possible Acute
Coronary Syndromes, n= 699) trials.30–32 Compared with stand-
ard care, CTCA reduced both the time required to establish a
diagnosis and the overall length of stay, albeit with no difference in
hard clinical outcomes. However, these trials were performed
prior to the introduction of high-sensitivity cardiac troponin
assays, which allow more rapid rule-out of myocardial infarction in
the Emergency Department setting.33,34 The more contemporary
BEACON (Better Evaluation of Acute Chest Pain with Coronary
Computed Tomography Angiography, n= 500) trial employed
such assays and perhaps consequently was unable to demonstrate
any benefit regarding length of stay with the use of CTCA.35 This
finding has been corroborated by a post hoc analysis of the
ROMICAT I and II trials where stored samples were used for the
measurement of high-sensitivity cardiac troponin I.36
Less evidence exists to inform the role of CTCA in the manage-
ment of asymptomatic patients at risk of cardiovascular disease, and
such an approach has been investigated in only a single trial to date.
The FACTOR-64 (Screening For Asymptomatic Obstructive
Coronary Artery Disease Among High-Risk Diabetic Patients Using
CT Angiography, Following Core 64) trial randomized 900 patients
with established diabetes mellitus but no prior history of cardiovascu-
lar disease to standard care or CTCA.37 Intensive treatment of co-
Figure 4 Coronary atherosclerosis T1-weighted characterization with integrated anatomical reference (CATCH). T1-weighted magnetic reson-
ance coronary angiogram of a patient who presented with an inferior myocardial infarction shows evidence of a focal high intensity lesion (arrows) in
the right coronary artery on magnetic resonance imaging (A and B). Subsequent coronary angiogram demonstrated occlusion of the mid-right coron-
ary artery (C) with restoration of flow following thrombus aspiration (D).
6 P.D. Adamson and D.E. Newby
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehy670/5156200 by Edinburgh U
niversity user on 16 N
ovem
ber 2018
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
morbid vascular risk factors was strongly encouraged in those
identified with coronary atheroma on non-invasive imaging. Due to
excellent use of preventative therapies in the standard care arm,
CTCA was associated with only a small incremental reduction in
cholesterol profiles and event rates were low in both treatment
groups; less than one quarter of that expected. Overall, despite a nu-
merical trend, no improvement in the primary composite cardiovas-
cular endpoint was identified (hazard ratio 0.69, 95% confidence
interval 0.41–1.16; P= 0.16).
Future research directions for computed
tomography coronary angiography
Having demonstrated the benefits of CTCA in the diagnosis of sus-
pected stable angina, further work is underway to test further roles
for this technique in clinical practice. The RAPID-CTCA (Rapid
Assessment of Potential Ischaemic Heart Disease with CTCA) trial is
a multicentre study recruiting patients with suspected acute coronary
syndrome and an additional risk factor; such as positive cardiac
troponin, ischaemic changes on the ECG, or an established history of
CAD. Patients will be randomized to early CTCA or standard care—
in many cases likely to include invasive coronary angiography. The
trial is powered with regards to the primary endpoint of all-cause
death or recurrent non-fatal myocardial infarction at 1-year and plans
to recruit 2500 patients.38 Another ongoing study of CTCA in the
acute coronary syndrome setting is the TARGET-CTCA (Troponin
in Acute chest pain to Risk stratify and Guide EffecTive use of
Computed Tomography Coronary Angiography) trial. This study
exploits the potential of high-sensitivity troponin to identify an at risk
subgroup of the suspected ACS population where the peak troponin
....................................................................................................................................................................................................................
Table 2 PETradiotracers for coronary atherosclerosis
Target Ligand Radiotracer Application to date Selected ongoing clinical trials
Macrophage
activation
GLUT (1 and 3) and conversion by
hexokinase to 18F-FDG-6-
phosphate
18F-FDG Prospective in vivo studies in
extracardiac atherosclerosis
Myocardial suppression required
to evaluate coronary arteries
Vascular Inflammation in Psoriasis
(NCT02187172, NCT03082729)
Somatostatin receptor subtype 2 68Ga-DOTATATE Prospective in vivo studies in car-
diac and extracardiac
atherosclerosis
Retrospective in vivo studies in
coronary artery disease
Translocator protein 18-kDa 11C-PK11195 Prospective in vivo study in ca-
rotid stenosis
Translocator protein 18-kDa 11C-PBR28 Clinical studies in healthy con-
trols and multiple sclerosis
Cardiac Sarcoidosis
(NCT02017522)
Mannose receptor 18F-FDM Preclinical cell culture model
Choline kinase phosphorylated to
Phosphatidylcholine
18F-choline Preclinical murine model ESCAPPE (NCT02640313)
Apoptosis Phosphatidylserine 68Ga-Annexin A5 Preclinical murine model
Hypoxia Reduction to amine derivative in low
O2 environment
18F-FMISO Preclinical murine model
Reduction to amine derivative in low
O2 environment
18F-HX4 Proof of concept in carotid
atherosclerosis
Microcalcification Hydroxyapatite 18F-fluoride Prospective in vivo studies in cor-
onary and extracardiac
atherosclerosis
PREFFIR Study (NCT02278211)
ROPPET-NAF (NCT03233243)
PET-MR Imaging In Patients With
Cardiac Amyloidosis
(NCT03626584)
Pilot Study-Magnetic Resonance
Imaging for Global Atherosclerosis
Risk Assessment (NCT02265250)
Angiogenesis aVb3 and aVb5 integrin 18F-Fluciclatide Prospective in vivo studies in car-
diac and extracardiac
atherosclerosis
aVb3 integrin 18F-RGD-K5 Ex vivo human carotid studies Carotid plaque imaging study
NCT01968226
Adapted from Moss et al.45
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concentration is mildly increased but remains below the 99th centile
upper reference limit. The trial is based on the premise that many of
these patients are currently discharged without a definitive aetiology
for their symptoms being established and that CTCA, by providing
diagnostic clarification, may allow better therapeutic targeting.
Magnetic resonance coronary
angiography
Magnetic resonance angiography is a widely accepted technique for
imaging larger conduit vessels, particularly the carotid arteries and ab-
dominal aorta. However, due to limitations related to spatial reso-
lution and long-scan times, coronary imaging with MRCA currently
has limited indications in clinical practice, except in the assessment of
anomalous coronary arteries, coronary aneurysms, and coronary by-
pass grafts. Nevertheless, MRCA has important potential strengths
that have maintained ongoing research interest. These include the
ability for luminal visualization in the presence of dense calcification,
the absence of ionizing radiation, the possibility for concomitant func-
tional imaging of the myocardium, and the potential for detailed tissue
characterization. A recently described example of the latter, is the
identification of high-intensity plaque on non-contrast T1-weighted
imaging (Figure 4).39 T1-weighted imaging targets methaemoglobin, a
component of thrombus and intraplaque haemorrhage, and high-
intensity plaque appears to be an MRCA analogue for low-density
plaque on CTCA that is associated with high-risk features on invasive
imaging with intravascular ultrasound or optical coherence tomog-
raphy.40,41 The presence of high-intensity plaque also correlates with
increased risk of procedure-related myocardial injury during percu-
taneous coronary intervention.39
Stepwise advances in imaging, moving from single-slice breath-hold
sequences, through free-breathing whole-heart scanning, and the
introduction of 3 Tesla magnets have brought a broader clinical role
Figure 5 Focal 18F-fluoride and 18F-fluorodeoxyglucose uptake in patients with myocardial infarction and stable angina. (Top row, A–C) Patient
with acute ST-segment elevation myocardial infarction with (A) proximal occlusion (red arrow) of the left anterior descending artery on invasive cor-
onary angiography and (B) intense focal 18F-fluoride uptake (yellow-red) at the site of the culprit plaque (red arrow) on the combined positron emis-
sion and computed tomography coronary angiography (PET-CTCA). Corresponding 18F-fluorodeoxyglucose PET-CT image (C) showing no uptake
at the site of the culprit plaque. Note the significant myocardial uptake overlapping with the coronary artery (yellow arrow) and uptake within the oe-
sophagus (blue arrow). (Bottom row) Patient with anterior non-ST-segment elevation myocardial infarction with (D) culprit (red arrow; left anterior
descending artery) and bystander non-culprit (white arrow; circumflex artery) lesions on invasive coronary angiography that were both stented dur-
ing the index admission. Only the culprit lesion had increased 18F-NaF uptake on PET-CT (E) after percutaneous coronary intervention.
Corresponding 18F-fluorodeoxyglucose PET-CT (F) showing no uptake either at the culprit or the bystander stented lesion. Note intense uptake
within the ascending aorta. Adapted from Joshi et al.47
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for MRCA closer. Nevertheless, in the assessment of suspected sta-
ble angina, MRCA currently has only modest diagnostic accuracy,
with a recent meta-analysis of 24 studies reporting a pooled sensitiv-
ity and specificity for the detection of >50% stenosis on invasive cor-
onary angiography of 89% and 72%, respectively.42 Whilst diagnostic
performance can be increased with the use of gadolinium-based
intravascular contrast agents, MRCA undoubtedly remains in its
infancy.
Positron emission tomography
Positron emission tomography is a non-invasive technique that is
underpinned by molecularly targeted probes, conjugated to a radio-
active isotope that undergoes beta decay. The probes vary widely in
regards to structural complexity but each is chosen in order to bind
with very high sensitivity to important components of a specific
pathophysiological process of interest. After binding, the emitted
positron travels a short distance in vivo before interacting with an
electron. The resultant annihilation releases two photons in opposing
directions which exit the body and are identified as coincident events
by the encircling detector ring.43 Even more so than with magnetic
resonance imaging, PET imaging of the coronary arteries has trad-
itionally been challenged by the problems of prolonged scan times,
spatial resolution and limited availability.44 Hybrid PET-CT and PET-
MR scanners have begun to address these challenges and coronary
PET imaging now appears to be a viable proposition. Although the
scope to manufacture probes for molecular imaging targets is near-
limitless, to date the majority of clinical research has related to three
tracers of interest (Table 2).
18F-Fluorodeoxyglucose
18F-Fluorodeoxyglucose (18F-FDG), a non-specific marker of cellular
inflammation was the first tracer to be investigated for coronary
imaging with preclinical models showing a correlation between tracer
uptake and increased macrophage activity.46 When used in vivo to
image the carotid arteries, 18F-FDG uptake correlates with high-risk
plaque features on CT and histological specimens. Carotid uptake
has also been demonstrated to identify a reduction in atherosclerotic
inflammation in response to treatment with simvastatin.47 Similar
associations within the coronary vasculature are likely, but imaging in
this location is made challenging by the intense myocardial uptake,
often overwhelming the coronary signal.48
18F-Fluoride
18F-Fluoride binds with high affinity to the exposed surface of hy-
droxyapatite, a key mineral component of vascular calcification.
Initially developed for the detection of bony metastases, it is now
recognized to enable the detection of early microscopic atheroscler-
otic calcification prior to the development of macroscopic calcifica-
tion on CT imaging.49 In this context, tracer binding demonstrates
intense signal in areas of active mineralization where large numbers
of microcalcific deposits are present throughout the plaque, increas-
ing strain on the fibrous cap, thereby potentially provoking plaque
rupture. In contrast to 18F-FDG, 18F-fluoride is not limited by myo-
cardial uptake and identifies the culprit artery in patients diagnosed
with acute myocardial infarction (Figure 5).48 The ability of coronary
imaging with 18F-fluoride PET-CT to improve risk stratification fol-
lowing myocardial infarction is currently being investigated in a pro-
spective multicentre trial (NCT02278211).
68Ga-DOTATATE
68Gallium-labelled DOTATATE binds to the somatostatin receptor
subtype 2 (SSTR2) found on the surface of macrophages, particularly
the proinflammatory M1 subtype. Preclinical studies suggest it may be
a superior marker of coronary macrophage activity than 18F-FDG
and importantly myocardial uptake is minimal. A recent report dem-
onstrates increased 68Ga-DOTATATE uptake in culprit coronary
and carotid plaques and correlation with CT and histological evi-
dence of high-risk plaque.50 Whether this information can be used to
inform patient management remains to be determined.
Conclusions
Non-invasive imaging of the coronary arteries is an enterprise in rapid
development. From the research perspective, there is great demand
for in vivo techniques that can reliably identify features of high-risk pla-
que that may offer insight into pathophysiological processes and act
as surrogate indicators of response to therapeutic intervention.
Meanwhile, there is clear clinical need for greater accuracy in symp-
tom diagnosis and prognostic stratification. Fortunately, constant
incremental enhancements in scanner technology and image post-
processing are helping make these elusive goals a reality. To date,
computed tomography, remains the most clinically applicable tech-
nique due to its broad availability and the strength of its evidence
base. Coronary calcium scoring appears to be a useful technique for
improving risk assessment in primary prevention, whilst CTCA is a
valuable diagnostic test that improves diagnostic certainty and
optimizes downstream management in symptomatic patients. At pre-
sent, MRCA and PET remain largely investigational imaging modalities
but landmark trials are now underway that will inform their future
clinical role.
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